论文部分内容阅读
目的:研究非霍奇金淋巴瘤(non-Hodgkin’s lymphoma,NHL)患者血浆D-二聚体(D-dimer)水平与NHL的临床病理学参数的关系。方法:ELISA法检测36例NHL患者血浆D-dimer的水平。结果:NHL患者D-dimer水平为(684.19±463.67)ng/mL,较对照组的(181.67±128.93)ng/mL显著升高(P <0.01)。侵袭性NHL D-dimer水平为(926.83±510.47)ng/mL,高于惰性NHL患者的(502.21±331.68)ng/mL(P<0.01)。LDH异常的NHL患者D-dimer水平为(463.89±109.22)ng/mL,高于LDH正常者的(365.39±311.93)ng/mL,差异具有显著性(P <0.01)。结论:NHL患者D-dimer血浆水平反映淋巴瘤患者的病情演变,有助于选择化疗方案和判断预后。
OBJECTIVE: To investigate the relationship between plasma D-dimer levels and clinicopathological parameters of NHL in patients with non-Hodgkin’s lymphoma (NHL). Methods: The plasma levels of D-dimer in 36 patients with NHL were detected by ELISA. Results: The D-dimer level in NHL patients was (684.19 ± 463.67) ng / mL, which was significantly higher than that in the control group (181.67 ± 128.93) ng / mL (P <0.01). The aggressive NHL D-dimer level was (926.83 ± 510.47) ng / mL higher than that of the inactive NHL patients (502.21 ± 331.68) ng / mL (P <0.01). The D-dimer level was (463.89 ± 109.22) ng / mL in NHL patients with abnormal LDH, which was significantly higher than that in patients with normal LDH (365.39 ± 311.93) ng / mL (P <0.01). Conclusion: The plasma levels of D-dimer in NHL patients reflect the evolution of patients with lymphoma, which will help to select the chemotherapy regimen and prognosis.